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Schlüsselwörter
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Zusammenfassung
Hintergund: Ziel dieser Pilotstudie war es, die Durchführ-
barkeit und Toxizität einer Chemotherapie mit Vinorelbin
und Mitomycin C in Kombination mit einer simultanen
Strahlentherapie (RT) bei Patienten mit lokal fortgeschrit-
tenen Kopf-Hals-Tumoren zu evaluieren. Patienten und
Methoden: Zwischen Januar 2003 und März 2004 wur-
den 15 Patienten mit T4/N2–3 Plattenepithelkarzinomen
(12/15) oder mit zervikalen N3-Lymphknotenmetastasen
bei unbekanntem Primärtumor (3/15) einer Chemothera-
pie und einer akzelerierten RT unterzogen. Ergebnisse:
Bei 11 Patienten konnte die Radiochemotherapie ohne
Unterbrechung oder Reduktion der Zielvolumendosis
durchgeführt werden. Eine akute Grad 3–4 Mukositis war
bei 9/15 Patienten, eine hämatologische Toxizität Grad 4
bei 6/15 Patienten nachweisbar. Im medianen Beobach-
tungszeitraum von 7,5 Monaten waren 2 Patienten an Be-
gleiterkrankungen verstorben und 2 entwickelten ein Lo-
kalrezidiv. 5 Patienten zeigten eine anhaltende komplette
Remission. Diskussion: Die verabreichte Radiochemothe-
rapie ist eine hoch wirksame Therapie für diese Patien-
ten, wird aber von wesentlichen akuten Nebenwirkungen
begleitet. 
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Summary
Objective: The purpose of this pilot study was to evalu-
ate the feasibility and toxicity of concurrent chemothera-
py with vinorelbine and mitomycin C in combination
with accelerated radiotherapy (RT) in patients with local-
ly advanced cancer of the head and neck. Patients and
Methods: Between January 2003 and March 2004, 15 pa-
tients with T4/N2–3 squamous cell carcinoma (12/15) and
with N3 cervical lymph node metastases of carcinoma of
unknown primary (3/15) were treated with chemotherapy
and simultaneous accelerated RT. Results: 11 patients
completed therapy without interruption or dose reduc-
tion. Grade 3–4 acute mucosal toxicity was observed in
9/15 patients, grade 4 hematologic toxicity in 6/15 pa-
tients. At a median follow-up of 7.5 months, 2 patients
have died of intercurrent disease, 2 patients have experi-
enced local relapse; 5 patients are alive with no evidence
of disease at the primary tumor site. Discussion: The de-
scribed regimen is highly effective, but led to remarkable
side effects. 
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Carcinoma of the head and neck is a frequent disease – each
year approximately 53,000 new cases are diagnosed in Western
Europe, usually associated with the abuse of alcohol and nico-
tine [1]. Most of the carcinomas are locally advanced at pre-
sentation. While in early stages many patients can be treated
in curative intention and the 5-year overall-survival is as high
as 70–90%, locally advanced disease is still difficult to treat. 
In general, surgery (or radiotherapy, RT) is the favored treat-
ment modality for smaller lesions (T1/T2), whereas more ad-
vanced stages (T3/T4, III/IV) are better treated with com-
bined surgery (if possible) and RT [2]. Platinum-based con-
comitant chemotherapy and RT is superior to conventional
RT alone in improving survival in locally advanced squamous
cell carcinoma of the head and neck (SCCHN) [3]. The use of
altered fractionation schedules (e.g. twice daily radiotherapy,
9–10 fractions per week) has allowed a significantly greater
proportion of patients with advanced head and neck tumors
to be cured with organ preservation [4]. Yet, even in relatively
favorable cases (e.g. T3), local relapses (30–60%) occur de-
spite all advances in treatment modalities including high
doses of radiotherapy and chemotherapy [5]. 20% of patients
with stage III/IV experience treatment failure due to distant
metastases. Improvements in loco-regional control and dis-
ease-free survival rates are often obtained at the price of
increased acute and late toxicity. 
Thus, there is a clear need for further improvement of the
therapeutic outcome in locally advanced SCCHN. Meta-
analyses seem to prove that patients with locally advanced
tumors achieve a modest, but statistically significant survival
benefit from concurrent chemo-radiation whereas neoadju-
vant and adjuvant chemotherapy did not convey a significant
survival advantage [6].
Among chemotherapeutic agents with activity against SC-
CHN, many drugs have been evaluated including cisplatin and
5-fluorouracil (5-FU). But response rates are moderate and
toxicity is increased [7], so research is continued to find effec-
tive and well tolerable drugs that can be used in combination
with radiotherapy. Taxanes, topoisomerase I inhibitors and
nucleoside analogues like gemcitabine, which might be potent
antitumor agents have been tested in recent phase I–II studies
with moderate to promising results. Treatment costs have also
to be included in considerations for treatment planning. 
Vinorelbine, a semisynthetic vinca alkaloid, acting through
disorganisation of microtubules during mitosis, is used as a
single agent in the treatment of advanced breast cancer,
where it induces a response rate of approximately 20% [8, 9].
Preclinical studies indicated a role for vinorelbine as a ra-
diosensitizer. A series of published studies have shown that
the use of vinorelbine and other drugs [10] such as cisplatin
and ifosfamide followed by carefully planned radiotherapy is
both adequately tolerated and able to achieve high response
rates together with improved survival in patients with locally
advanced NSCLC [11].
Mitomycin C is frequently used for this disease entity. Given
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concomitantly to radiotherapy mitomycin C improves long-
term tumor control [12, 13]. In combination with fractionated
irradiation, mitomycin C significantly reduces the risk of local
recurrences and inhibits tumor cell repopulation in vivo in
fast growing squamous cell carcinoma in mice, thus indicating
its function as a radiosensitizer [14]. The combination of mito-
mycin C and vinorelbine in patients with metastatic breast
cancer was proven effective and well tolerable with response
rates of 35–73% [14–16]. Conti et al. even found response
rates of up to 92% for the treatment of breast cancer for this
combination [17]. 
Our aim was to evaluate the activity and toxicity of an intensi-
fied regimen containing vinorelbine and mitomycin C in com-
bination with accelerated radiotherapy in patients with locally
advanced squamous cell carcinoma of the head and neck.
Patients and Methods
Patient Characteristics
From January 2003 to March 2004, 15 male patients with locally advanced
T4/N2–3 SCCHN and N3 cervical lymph node metastases of carcinoma of
unknown primary (CUP) were treated with accelerated radiotherapy
(57.6 Gy over 5 weeks, boost of 14.0 Gy) and concurrent chemotherapy
with vinorelbine (25 mg/m2 on day 1, 8, 22, 29) and mitomycin C (8 mg/m2
on day 1 and 29). 12/15 patients (80%) with SCCHN had T4N+ disease,
3/15 patients (20%) had N3 cervical lymph nodes of carcinoma of un-
known primary and had been judged unresectable. None of the patients
had received radiotherapy before. 2 patients had distant metastases 
(1 lung, 1 lung and liver). 4 patients suffered from severe other diseases: 
1 patient with HIV-infection had been under antiviral treatment for 
15 years, 1 patient suffering from pemphigus required constant therapy
with steroids. 1 patient had liver cirrhosis (Child A). 1 patient suffering
from rheumatoid arthritis had been pretreated with low doses of metho-
trexate for months. All patients had a history of alcohol and/or nicotine
Characteristics
Median age, years (range) 58 (45–71)

n (%)

Patients 15 (100)
Distant metastases 2 (13)
Histology
Squamous cell carcinoma G2a 7 (47)
Squamous cell carcinoma G3a 7 (47)
First-line therapy, n 15 (100)
Predominant site of disease
Oropharynx 2 (13)
Hypopharynx 2 (13)
More than one region 6 (40)
Larynx 1 (7)
Nasopharynx 1 (7)
N3 cervical lymph nodes (CUP) 3 (20)
a One patient: squamous cell carcinoma, not
classified.
Table 1. Patient
characteristics
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abuse. 2 patients had required psychological assistance during previous
treatment due to alcoholic delirium.
All patients had histologically confirmed squamous cell carcinoma. In all
patients computer tomography and/or magnetic resonance imaging scans
of the head and neck region as well as CT scans of the lung and CT scans
of the abdomen and/or liver sonography were performed to evaluate dis-
tant metastases before the start of therapy. All patients had a Karnofsky
performance status > 60%, white blood count > 3500/mm3, platelet count
> 100,000/µl, serum creatinine level inside normal range and bilirubin 
< 1.5 mg/d (table 1).
Treatment and Evaluation 
Chemotherapy. Vinorelbine was given intravenously at the dose of 
25 mg/m2 on day 1, 8, 22, 29, mitomycin C at the dose of 8 mg/m2 on day 
1 and 29 (fig. 1). For prevention of anaphylactoid reactions through mito-
mycin C prednisone (i.v.) was given prior to application. All patients re-
ceived prophylaxis of mucositis, including aqueous mouth rinse contain-
ing chlorhexidine gluconate, dexpanthenol solutions and oral ampho-
tericin B. Oral fluconazol was given in case of grade IV neutropenia or in
case of grade III or IV mucositis; in case of febrile neutropenia, intra-
venous antibiotic therapy was started with tazobactam/piperacillin and
was adapted to antibiotic resistance testing if possible. The patient’s
weight was monitored weekly, and nutritional support with parenteral
nutrition was planned when weight loss would exceed approximately
10%. 2 patients had a feeding tube placed before treatment. Toxicity was
categorized according to WHO criteria. Hematological toxicity was as-
sessed by repeated blood counts at least once a week. 
Radiotherapy. All radiation fields were delivered with 6 MV photons by
linear accelerator; all patients received 3D plans to assess dose homo-
geneity in the target volume. Patients were treated in supine position
using individualized head immobilization devices. The target volume in-
cluded the primary tumor area and local-regional lymph nodes. For radio-
therapy we used a regimen very well established for years in our depart-
ment: The prescribed dose for tumor region and clinically involved lymph
nodes was 57.6 Gy. All 15 patients were treated with accelerated radio-
therapy twice daily with fractions of 1.8 Gy each, separated by 6 h on
Monday, Tuesday, Thursday and Friday (only one fraction on Wednes-
days). After 32.4 Gy, an 8.0 Gy boost was given only to the regions of
macroscopic tumor at fractions of 2.0 Gy once daily. Another boost of 
6.0 Gy to the same regions was given at the end of therapy. The cumula-
tive dose of those patients was 71.6 Gy (fig. 1). Uninvolved lymphatic
regions (neck and supra-/infraclavicular regions) were treated with a dose
of 52.2 Gy. Multileaf collimators were used to limit irradiation to the
surrounding normal tissues. Maximum spinal cord dose was limited to
<40.0 Gy. Electron beams were used if necessary to achieve the pre-
scribed dose in the nuchal and paravertebral regions. The dose was calcu-
lated according to ICRU 50/70. 
Response. Primary response was evaluated by clinical examination and
CT scan imaging approximately 3 months after completion of therapy, ad-
ditional evaluation was done after 6 and 12 months, if possible. Complete
response was defined as the disappearance of all local disease sites (pri-
mary tumor, local lymph node metastases). Partial response was defined
as a decrease of 50% or more in the sum of the largest perpendicular
diameters of measurable lesions, with no appearance of new lesions and
no progression of any lesion. Stable disease was defined as decrease of
less than 50% with no increase in measurable tumor volume.
Results
Acute Toxicity
All patients had mild to severe mucositis; 2 (13%) patients
experienced grade IV, 7 (47%) patients grade III mucositis; 
6 (40%) patients had grade IV and 4 (27%) patients had
grade III leukopenia. 12/15 (80%) patients required parenter-
al nutrition (table 2). 4/15 (27%) patients required G-CSF-
support. 4/15 (27%) patients required red blood cell trans-
fusions. 4/15 (27%) patients were treated with parenteral an-
tibiotics because of febrile neutropenia. No patient required
platelet transfusions. Interruption of radiotherapy for 1–3
days was necessary in 3 patients because of infection, low
WBC counts or noncompliance. No patient had cardiac toxic-
ity or neurotoxicity. No patient complained of nausea or vom-
iting, no patient experienced pulmonary toxicity, alopecia or
other, non-hematologic, not mucosa-associated toxicity.
Late Toxicity
All patients experienced mild cutaneous fibrosis and moder-
ate xerostomia. 3/15 patients (20%) experienced severe late
toxicity: 1 patient had perichondritis, requiring hospitalization
and parenteral nutrition for several days; 2 patients com-
plained of dysphagia through stenosis of the upper esophagus,
leading to significant weight loss and placement of a feeding
tube 6 months after completion of radiochemotherapy in 
1 patient and to necessity of repeated dilatation treatment in
the other patient (table 3).
Tumor Response
After a median follow-up of 7.5 months 5 patients (33%)
achieved complete remission and 8 patients (53%) achieved a
partial remission as determined 3 months after completion of
treatment (table 4). The histological grading had no influence
on response rates. 1/8 patients with a partial remission experi-
enced relapse in a nuchal lymph node after 8 months and 
1/8 patients showed a local recurrence in the region of the
hypopharynx, where the maximum dose had been applied.
 RT 1.8 Gy b.i.d. (6h) 4x2 Gy 1.8 Gy b.i.d. (6h) 
Boost 
3x2 Gy  
Boost 
Total 
7160 cGy
Vinorelbine 25 mg/m
2
Mitomycin C 8 mg/m
2
 
wk 1 2 3 4 5 
 
Fig. 1. Treatment plan
Table 2. Acute toxicity 
Toxicity Grade

I II III IV
Mucositis, n 2 (13%) 4 (27%) 7 (47%) 2 (13%)
Leucopenia, n 2 (13%) 3 (20%) 4 (27%) 6 (40%)
Dysphagia, n 1 (7%) 2 (13%) 12 (80%) –
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Distant failure alone occurred in 1/12 patients (in addition to
2 patients having already known metastases). One patient
died of intercurrent infection 4 months after completion of
treatment. Another patient died of gastro-intestinal bleeding
two months after completion of treatment. At the time of
evaluation (March 2004), 8/15 patients were alive with no evi-
dence of disease at the primary tumor site.
Discussion
In a meta-analysis Pignon et al. [18] showed that benefit in
overall survival and local control is greatest with concomitant
chemotherapy and altered fractionated radiotherapy. To our
knowledge, this is the first reported experience evaluating the
tolerability and efficacy of concurrent chemotherapy with vi-
norelbine and mitomycin C and accelerated radiotherapy in
patients with locally advanced SCCHN and N3 cervical lymph
node metastases of CUP. The unique features and potential
advances associated with this chemoradiation regimen are
local and systemic synergistic anti-tumor effects of two
chemotherapeutic agents and radiation therapy. The use of
accelerated RT shortens overall treatment time and enables
radiation dose escalation with associated improved local tu-
mor control. 
Compared with previously reported chemoradiation experi-
ences for SCCHN, our regimen of accelerated RT and
chemotherapy with vinorelbine and mitomycin C has been as-
sociated with severe but similar side effects. Reported studies
have shown grade III/IV acute toxicity rates of > 50% and
mortality rates up to 8% [19–21]. Specific toxicities and rates
include grade IV hematologic toxicity in 10–55% [20–22],
grade IV mucosal toxicity in 13–18% [20–22] and grade III/IV
neurologic toxicity in 2–6% of patients [23, 24]. In comparison
with a prospective, randomized study of Budach et al. [25],
who combined 5-FU and mitomycin C with a hyperfractionat-
ed accelerated radiation therapy, the rate of grade III/IV mu-
cositis (65.7%) was similar to our results (60%). Grade III
leucopenia was observed in 8.5%, no patient showed grade IV
leucopenia, whereas in our study the rate of grade III/IV leu-
copenia was very high (27 and 40%).
Harrison et al. [26] treated 52 patients with unresectable tu-
mors of the head and neck region with RT (accelerated frac-
tionation, total 70 Gy in concomitant-boost technique) and
chemotherapy (cisplatin or mitomycin C). They found mito-
mycin C to be too myelosuppressive and therefore eliminated
this substance from their program. 
Another study, the IAEA multicentre randomised trial, re-
ports very low hematological side effects (< 5% grade III/IV)
of mitomycin C (one single injection of 15 mg/m2) in combina-
tion with conventional fractionated radiotherapy in patients
with locally advanced head and neck cancer [27]. Our grade
IV hematologic toxicity rate of 40% seems to be unacceptably
high, so the chemotherapy dose was reduced for the recently
started phase II study. 
Two accelerated schedules, CHART [28] and RTOG 9101 [29]
have been associated with a significant reduction in the inci-
dence of late normal tissue morbidity compared with conven-
tional fractionation [1]. However, there is a significant in-
crease in the incidence of fibrosis in the accelerated fractiona-
tion arm of the EORTC 22851 trial, supported by evidence
from other clinical and experimental studies. In our patients,
severe late toxicity consisted of one case of perichondritis
requiring hospitalization for several days and in two cases of
stenosis of the upper esophagus through fibrosis.
Other treatment strategies, such as hyperfractionated acceler-
ated radiotherapy combined with intra-arterial cisplatin infu-
sions [5] have shown promising results, but can only be per-
formed in few patients with limited tumor extension. Selective
lymph node dissection after accelerated chemoradiation with
mitomycin C/5-FU to a dose of 70.6 Gy is likely to contribute
to loco-regional tumor control in advanced head and neck
cancer patients, as reported by Hehr et al. [30]. Our response
rate of 86% in a highly unfavorable patient collective can not
be interpreted yet due to short follow-up time but seems to be
comparable or even more favorable than other regimens with
intensive chemoradiation. A prospective randomized trial is
necessary to evaluate the efficacy of this treatment regimen.
In conclusion, chemoradiotherapy with vinorelbine and mito-
mycin C and accelerated RT as used in our patients was asso-
ciated with a high response rate but also with a high rate of
grade III/IV acute toxicity concerning mucositis and low
white blood cell counts. Our findings appear comparable to
previously reported chemoradiation regimens in similar pa-
tients. The described regimen with less intensive chemothera-
py is currently under study with the intent of optimizing maxi-
mally tolerable and efficacious therapy in patients with locally
advanced SCCHN. To evaluate pathologic response and to
further improve the prognosis of those patients, surgical re-
section after radiochemotherapy is another treatment option
that is discussed individually for every patient.
Toxicity Patients, n
Cutanous fibrosis, mild 15 (100%)
Xerostomia, moderate 15 (100%)
Perichondritis 1 (7%)
Stenosis of the upper esophagus 2 (13%)
Table 3. Late toxicity 
Response Patients, n 
Complete response 5 (33%)
Partial response 8 (53%)
Stable disease 2 (13%)
Table 4. Tumor res-
ponse after a median
follow-up of 7.5
months
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